Financial Personal
Delve Bio Presents Data Showing Metagenomic Next-Generation Sequencing (mNGS) Delivers Greater Diagnostic Yield Than Conventional Methods in Central Nervous System Infections
In the largest study of its kind, the diagnostic yield of mNGS was greater than conventional test methods mNGS alone identified 34% more pathogens than all direct-detection methods combined 72% of pathogens detected by mNGS would have been missed by
BOSTON -- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data from a seven-year study showing mNGS delivered the highest diagnostic yield of any test, identifying more pathogens than all other methods of direct organism detection (culture, antigen testing, PCR) combined. The findings were presented at the Association for Molecular Pathology 2024 Annual Meeting in Vancouver, B.C. Read More
